RENOVARO INC (RENB) Stock Price, Quote, News and Overview
NASDAQ:RENB - Nasdaq - US29350E1047 - Common Stock - Currency: USD
RENB Quote, Performance and Key Statistics
RENOVARO INC
NASDAQ:RENB (2/5/2025, 8:23:57 PM)
After market: 0.7003 -0.03 (-3.69%)0.7271
+0.03 (+3.8%)
The current stock price of RENB is 0.7271 USD. In the past month the price decreased by -27.29%. In the past year, price decreased by -78.74%.
RENB Latest News, Press Releases and Analysis
Renovaro Issues Shareholder Letter and Provides Corporate Update
Renovaro Appoints Nathen Fuentes as Chief Financial Officer
Renovaro Appoints Nathen Fuentes as Chief Financial Officer
Renovaro Appoints Nathen Fuentes as Chief Financial Officer...
Renovaro Issues Shareholder Letter and Provides Corporate Update
Renovaro Issues Shareholder Letter and Provides Corporate Update...
RENB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.95 | 338.85B | ||
| AMGN | AMGEN INC | 15.53 | 165.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 957.73 | 125.79B | ||
| GILD | GILEAD SCIENCES INC | 22.49 | 124.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.7 | 78.76B | ||
| ARGX | ARGENX SE - ADR | N/A | 40.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.64B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.34B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.26B | ||
| NTRA | NATERA INC | N/A | 23.37B | ||
| BIIB | BIOGEN INC | 8.91 | 21.21B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.55 | 15.81B |
Related stock screener links
About RENB
Company Profile
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 25 full-time employees. The company went IPO on 2014-11-18. The firm operates through two subsidiaries: Renovaro Biosciences, Inc. (Renovaro Biosciences) and Renovaro Cube. Renovaro Biosciences is a biotechnology company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed an AI platform that analyzes genetics using Explainable AI to provide earlier and more accurate cancer diagnosis. This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
Company Info
RENOVARO INC
Century City Medical Plaza, 2080 Century City East, Suite 906
Los Angeles CALIFORNIA US
Employees: 12
Company Website: https://renovarobio.com/
Investor Relations: http://www.enochianbio.com/investors-media/stock-info/
Phone: 14539179840
RENB FAQ
What is the stock price of RENB?
The current stock price of RENB is 0.7271 USD.
What is the symbol for RENOVARO INC stock?
The exchange symbol of RENOVARO INC is RENB and it is listed on the Nasdaq exchange.
On which exchange is RENB stock listed?
RENB stock is listed on the Nasdaq exchange.
Is RENB a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for RENB, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of RENB.
Does RENB stock pay dividends?
RENB does not pay a dividend.
When does RENB stock report earnings?
RENB will report earnings on 2025-02-12.
What is the Price/Earnings (PE) ratio of RENB?
RENB does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.93).
What is the Short Interest ratio of RENB stock?
The outstanding short interest for RENB is 8.17% of its float.
RENB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to RENB. When comparing the yearly performance of all stocks, RENB is a bad performer in the overall market: 91.32% of all stocks are doing better.
RENB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to RENB. While RENB seems to be doing ok healthwise, there are quite some concerns on its profitability.
RENB Financial Highlights
Over the last trailing twelve months RENB reported a non-GAAP Earnings per Share(EPS) of -0.93. The EPS decreased by -33.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -94.96% | ||
| ROE | -117.94% | ||
| Debt/Equity | 0 |